Categories: News

Cullinan Oncology Announces Management Transition

CAMBRIDGE, Mass., May 21, 2021 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today announced that Jon Wigginton, M.D. is stepping down from his day-to-day role as Chief Medical Officer, and will assume the role of Chairman of the company’s Scientific Advisory Board (SAB) and Senior Advisor to the CEO.

“I want to thank Jon for his many contributions to Cullinan, having helped the company transition to a public, clinical-stage biotech company, and establishing the clinical infrastructure necessary to run multiple global clinical trials,” stated Owen Hughes, Cullinan’s Chief Executive Officer. “More importantly, I’m delighted that we will continue to benefit from Jon’s experience and clinical development expertise as we progress a diversified pipeline of novel targeted and immuno-oncology agents into the clinic.”

“I am pleased to continue to work with Owen and my valued colleagues at Cullinan in our quest to help those living with cancer,” stated Dr. Wigginton. “I am looking forward to further assisting the outstanding team at Cullinan, and to providing strategic oversight of the depth and breadth of Cullinan’s innovative development programs.”

About Cullinan Oncology

Cullinan Oncology is a biopharmaceutical company that strives to deliver results for our various stakeholders through disciplined capital allocation, decisive action, prudent risk taking and creative business development. We seek to drive shareholder returns by focusing on the patient. The Company’s strategy is to build a diversified pipeline of targeted and immuno-oncology therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that it believes have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes. Learn more about Cullinan at www.cullinanoncology.com.

Contacts:

Investor Relations
investors@cullinanoncology.com

Jeffrey Trigilio
+1 617.410.4650
jtrigilio@cullinanoncology.com

Staff

Recent Posts

Nano Dimension to Acquire Desktop Metal, Creating a Leader in Additive Manufacturing

Well-Capitalized Combined Company with Strong Financial Profile and 2023 Revenue of $246M, 28% from Recurring…

21 mins ago

CHOWIS to Develop Customized Cosmetics Diagnostic Platform in Partnership With Kolmar Korea

Chowis Co. Ltd. Skin, Hair and Scalp Solutions Provider Signs Agreement with Kolmar Korea to…

23 mins ago

Rose Villa Senior Living and The Malden Collective Partner to Launch the LiveWell(R) Tech Accelerator

PORTLAND, OR / ACCESSWIRE / July 3, 2024 / Rose Villa Senior Living continues to…

23 mins ago

Delota Reports First Quarter Revenue of $9.9 Million and Positive Adjusted EBITDA

Highlights:Total revenue of $9.9 million for Q1 2025, reflecting YoY growth of 31% from the…

1 hour ago

Therma Bright Q2, 2024 Market Update On Business

Medical Device Developer & Investor Taps 4 Markets With Growth Projections of USD $39.1B by…

2 hours ago

Danish start-up Kvantify secures EUR 10 million seed round to unlock quantum computing potential, starting with life sciences

The round is led by Danish VC Dreamcraft, together with biotech investor Lundbeckfonden BioCapital and…

3 hours ago